Eledon Pharmaceuticals Inc (ELDN) Stock Analysis

Eledon Pharmaceuticals Inc (ELDN) is a publicly traded company in the HEALTHCARE sector. It trades at $3.53, carries a market capitalization of $294.09M. This page summarizes the public market data, fundamentals, and frequently asked questions for ELDN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.53
• Market Cap: $294.09M
• EPS: $-0.77
• 52-Week High: $4.60
• 52-Week Low: $1.35

Market Sentiment

Eledon Pharmaceuticals Inc currently has a Bullish sentiment score of 0.46.

About Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to innovating therapies for patients with autoimmune diseases and amyotrophic lateral sclerosis (ALS), particularly those in need of organ or cell transplantation. Based in Irvine, California, Eledon is advancing its proprietary drug candidates through clinical trials, aiming to address significant unmet medical needs in these patient populations. With a robust pipeline and a strategic focus on enhancing tran...

GNG Research Analysis

GNG Research scores Eledon Pharmaceuticals Inc (ELDN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ELDN.

Frequently Asked Questions

Does ELDN pay dividends?

Eledon Pharmaceuticals Inc (ELDN) does not currently pay a regular dividend.

What is ELDN's market cap?

Eledon Pharmaceuticals Inc (ELDN) has a market capitalization of $294.09M with a current stock price of $3.53.